Oriol Mitjà1,2,3, Marc Corbacho-Monné1,4, Maria Ubals2,4, Cristian Tebé5, Judith Peñafiel5, Aurelio Tobias6, Ester Ballana7, Andrea Alemany1, Núria Riera-Martí1, Carla A Pérez1, Clara Suñer1, Pep Laporte1, Pol Admella1, Jordi Mitjà1, Mireia Clua1, Laia Bertran1, Maria Sarquella1, Sergi Gavilán1, Jordi Ara2, Josep M Argimon8, Jordi Casabona9,10, Gabriel Cuatrecasas11, Paz Cañadas12, Aleix Elizalde-Torrent7, Robert Fabregat13, Magí Farré2, Anna Forcada14, Gemma Flores-Mateo15, Esteve Muntada9, Núria Nadal16, Silvia Narejos17, Aroa Nieto1, Nuria Prat18, Jordi Puig1, Carles Quiñones2, Juliana Reyes-Ureña9,10, Ferran Ramírez-Viaplana1, Lidia Ruiz7, Eva Riveira-Muñoz7, Alba Sierra1, César Velasco19, Rosa Maria Vivanco-Hidalgo19, Alexis Sentís9, Camila G-Beiras1, Bonaventura Clotet1,7,20, Martí Vall-Mayans1,2. 1. Fight AIDS and Infectious Diseases Foundation, Badalona, Spain. 2. Hospital Universitari Germans Trias i Pujol and Universitat Autònoma de Barcelona, Badalona, Spain. 3. Lihir Medical Centre-International SOS, Lihir Island, Papua New Guinea. 4. Facultat de Medicina, Universitat de Barcelona, Barcelona, Spain. 5. Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Spain. 6. Institute of Environmental Assessment and Water Research (IDAEA), Spanish Council for Scientific Research (CSIC), Barcelona, Spain. 7. IrsiCaixa AIDS Research Institute, Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain. 8. Direcció-gerència, Institut Català de la Salut, Barcelona, Spain. 9. Centre of Epidemiological Studies of HIV/AIDS and STI of Catalonia (CEEISCAT), Catalan Institute of Oncology (ICO)-Departament de Salut, Generalitat de Catalunya, Barcelona, Spain. 10. Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain. 11. Equip d'atenció primària de Sarria, Barcelona, Spain. 12. SYNLAB, Barcelona, Spain. 13. Direcció General de Recerca i Innovació en Salut, Generalitat de Catalunya, Barcelona, Catalonia, Spain. 14. Gerència territorial de Catalunya Central, Institut Català de la Salut, St Fruitós del Bages, Spain. 15. Xarxa Sanitària i Social Santa Tecla, Tarragona, Spain. 16. Gerència territorial de Barcelona, Institut Català de la Salut, Barcelona, Spain. 17. Entitat de Base Asociativa Centelles- Atenció Primària, Centelles, Spain. 18. Gerència territorial de Àmbit Metropolità nord, Institut Català de la Salut, Sabadell, Spain. 19. Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS), Barcelona, Spain. 20. Universitat de Vic-Universitat Central de Catalunya (UVIC-UCC), Vic, Spain.
Abstract
BACKGROUND: No effective treatments for coronavirus disease 2019 (COVID-19) exist. We aimed to determine whether early treatment with hydroxychloroquine (HCQ) would be efficacious for outpatients with COVID-19. METHODS: Multicenter open-label, randomized, controlled trial conducted in Catalonia, Spain, between 17 March and 26 May 2020. Patients recently diagnosed with <5-day of symptom onset were assigned to receive HCQ (800 mg on day 1 followed by 400 mg once daily for 6 days) or usual care. Outcomes were reduction of viral load in nasopharyngeal swabs up to 7 days after treatment start, disease progression up to 28 days, and time to complete resolution of symptoms. Adverse events were assessed up to 28 days. RESULTS: A total of 293 patients were eligible for intention-to-treat analysis: 157 in the control arm and 136 in the intervention arm. The mean age was 41.6 years (SD, 12.6), mean viral load at baseline was 7.90 log10 copies/mL (SD, 1.82), and median time from symptom onset to randomization was 3 days. No differences were found in the mean reduction of viral load at day 3 (-1.41 vs -1.41 log10 copies/mL in the control and intervention arm, respectively) or at day 7 (-3.37 vs -3.44). Treatment did not reduce risk of hospitalization (7.1% control vs 5.9% intervention) nor shorten the time to complete resolution of symptoms (12 days, control vs 10 days, intervention). No relevant adverse events were reported. CONCLUSIONS: In patients with mild COVID-19, no benefit was observed with HCQ beyond the usual care.
BACKGROUND: No effective treatments for coronavirus disease 2019 (COVID-19) exist. We aimed to determine whether early treatment with hydroxychloroquine (HCQ) would be efficacious for outpatients with COVID-19. METHODS: Multicenter open-label, randomized, controlled trial conducted in Catalonia, Spain, between 17 March and 26 May 2020. Patients recently diagnosed with <5-day of symptom onset were assigned to receive HCQ (800 mg on day 1 followed by 400 mg once daily for 6 days) or usual care. Outcomes were reduction of viral load in nasopharyngeal swabs up to 7 days after treatment start, disease progression up to 28 days, and time to complete resolution of symptoms. Adverse events were assessed up to 28 days. RESULTS: A total of 293 patients were eligible for intention-to-treat analysis: 157 in the control arm and 136 in the intervention arm. The mean age was 41.6 years (SD, 12.6), mean viral load at baseline was 7.90 log10 copies/mL (SD, 1.82), and median time from symptom onset to randomization was 3 days. No differences were found in the mean reduction of viral load at day 3 (-1.41 vs -1.41 log10 copies/mL in the control and intervention arm, respectively) or at day 7 (-3.37 vs -3.44). Treatment did not reduce risk of hospitalization (7.1% control vs 5.9% intervention) nor shorten the time to complete resolution of symptoms (12 days, control vs 10 days, intervention). No relevant adverse events were reported. CONCLUSIONS: In patients with mild COVID-19, no benefit was observed with HCQ beyond the usual care.
Authors: João João Mendes; José Artur Paiva; Filipe Gonzalez; Paulo Mergulhão; Filipe Froes; Roberto Roncon; João Gouveia Journal: Rev Bras Ter Intensiva Date: 2022-01-24
Authors: Cristhieni Rodrigues; Rodrigo S Freitas-Santos; José Eduardo Levi; Andreza A Senerchia; Ana Tarina A Lopes; Sergio R Santos; Rinaldo F Siciliano; Lígia C Pierrotti Journal: Int J Antimicrob Agents Date: 2021-08-25 Impact factor: 5.283
Authors: Gail Hayward; Christopher C Butler; Ly-Mee Yu; Benjamin R Saville; Nicholas Berry; Jienchi Dorward; Oghenekome Gbinigie; Oliver van Hecke; Emma Ogburn; Hannah Swayze; Emily Bongard; Julie Allen; Sharon Tonner; Heather Rutter; Sarah Tonkin-Crine; Aleksandra Borek; David Judge; Jenna Grabey; Simon de Lusignan; Nicholas P B Thomas; Philip H Evans; Monique I Andersson; Martin Llewelyn; Mahendra Patel; Susan Hopkins; F D Richard Hobbs Journal: BMJ Open Date: 2021-06-18 Impact factor: 2.692
Authors: Augusto Di Castelnuovo; Simona Costanzo; Antonio Cassone; Roberto Cauda; Giovanni De Gaetano; Licia Iacoviello Journal: Pathog Glob Health Date: 2021-06-15 Impact factor: 2.894